Engineered T cells for cancer treatment

Usanarat Anurathapan; Ann M. Leen; Malcolm K. Brenner; Juan F. Vera

doi:10.1016/j.jcyt.2013.10.002

Engineered T cells for cancer treatment

Usanarat Anurathapan, Ann M. Leen, Malcolm K. Brenner, Juan F. Vera

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.

Original language	English (US)
Pages (from-to)	713-733
Number of pages	21
Journal	Cytotherapy
Volume	16
Issue number	6
DOIs	https://doi.org/10.1016/j.jcyt.2013.10.002
State	Published - Jun 2014

Keywords

Cancer treatment
CAR T cells
Genetic modification of T cells
Immunotherapy

ASJC Scopus subject areas

Immunology
Immunology and Allergy
Oncology
Genetics(clinical)
Transplantation
Cancer Research
Cell Biology

Access to Document

10.1016/j.jcyt.2013.10.002

Cite this

@article{5aa598f4ea7a4ae69ef481dc79d3cb29,

title = "Engineered T cells for cancer treatment",

abstract = "Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.",

keywords = "Cancer treatment, CAR T cells, Genetic modification of T cells, Immunotherapy",

author = "Usanarat Anurathapan and Leen, {Ann M.} and Brenner, {Malcolm K.} and Vera, {Juan F.}",

note = "Funding Information: UA is supported by the Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. We are grateful for long-term support from the (U.S. National Institutes of Health National Cancer Institute and National Heart, Lung and Blood Institute) , the Department of Defense and the Leukemia and Lymphoma Research Fund. We are also grateful to the foundations that have supported the center's investigators, including Alex's Lemonade Stand, V Foundation , Dana Foundation , James S. McDonnell Foundation and Adrienne Helis Medical Research Foundation . ",

year = "2014",

month = jun,

doi = "10.1016/j.jcyt.2013.10.002",

language = "English (US)",

volume = "16",

pages = "713--733",

journal = "Cytotherapy",

issn = "1465-3249",

publisher = "Informa Healthcare",

number = "6",

}

TY - JOUR

T1 - Engineered T cells for cancer treatment

AU - Anurathapan, Usanarat

AU - Leen, Ann M.

AU - Brenner, Malcolm K.

AU - Vera, Juan F.

N1 - Funding Information: UA is supported by the Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. We are grateful for long-term support from the (U.S. National Institutes of Health National Cancer Institute and National Heart, Lung and Blood Institute) , the Department of Defense and the Leukemia and Lymphoma Research Fund. We are also grateful to the foundations that have supported the center's investigators, including Alex's Lemonade Stand, V Foundation , Dana Foundation , James S. McDonnell Foundation and Adrienne Helis Medical Research Foundation .

PY - 2014/6

Y1 - 2014/6

N2 - Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.

AB - Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.

KW - Cancer treatment

KW - CAR T cells

KW - Genetic modification of T cells

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84899932784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899932784&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2013.10.002

DO - 10.1016/j.jcyt.2013.10.002

M3 - Article

C2 - 24239105

AN - SCOPUS:84899932784

VL - 16

SP - 713

EP - 733

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 6

ER -

Engineered T cells for cancer treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this